Company: BIAF
Filing Date: 2025-10-27
Form Type: PRER14A
Source: 0001493152-25-019752
Chunk: 37

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-27
Form: PRER14A
Chunk 37
---
 Eastern Time on December 18, 2025. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS

If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.

VOTE BY PHONE - 1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions up until 11:59 p.m. Eastern Time December 18, 2025. Have your proxy card in hand when you call and then follow the instructions.

VOTE BY MAIL

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

TO VOTE, MARK BLOCK BELOW IN BLUE OR BLACK INK AS FOLLOWS:

KEEP THIS PORTION FOR YOUR RECORDS

DETACH AND RETURN THIS PORTION ONLY

<div align='center'>THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.</div>

BIOAFFINITY TECHNOLOGIES, INC.

The Board recommends a vote “FOR” Proposals 1, 2, 3, 4 and 5.

| 1. | Proposal to consider and                                                                                                              
 approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 271,500 shares of our Common Stock upon the exercise 
 of our common stock purchase warrants issued in connection with our private placement offering that closed on August 14, 2025, that   
 may be equal to or exceed 20% of our Common Stock outstanding before such offering (the “Warrant Exercise Proposal”).                 |

<div align='center'>FOR☐ AGAINST☐ ABSTAIN☐</div>

| 2. | Proposal to consider and                                                                                                                
 approve, pursuant to Nasdaq listing rules, the issuance of up to an aggregate of 365,620 shares of our Common Stock upon the triggering 
 of certain anti-dilution provisions of our common stock purchase warrants issued in connection with our private placement offering